LLY Form 4: director adds 12.259 shares; total 74,763.656
Rhea-AI Filing Summary
Eli Lilly (LLY) director transaction: On 10/20/2025, director J. Erik Fyrwald reported acquiring 12.259 shares at $808.96. The filing notes the director elected to defer cash compensation into stock units under the Lilly Directors' Deferral Plan, to be settled in common shares after separation from service. Following the entry, beneficial ownership stands at 74,763.656 shares, held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 12.259 shares
Net Buy
1 txn
Insider
Fyrwald J Erik
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 12.259 | $808.96 | $10K |
Holdings After Transaction:
Common Stock — 74,763.656 shares (Direct)
Footnotes (1)
- F1. At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.
FAQ
What did Eli Lilly (LLY) disclose in this Form 4?
A director reported acquiring 12.259 shares at $808.96 on 10/20/2025.
Who is the reporting person in LLY’s Form 4?
The reporting person is J. Erik Fyrwald, listed as a Director.
Was this an open-market purchase by the LLY director?
The filing states the director deferred cash compensation into stock units under the Lilly Directors' Deferral Plan, to be settled in shares after separation.
What is the ownership form of the reported LLY holdings?
The holdings are reported as Direct (D) ownership.
AI-generated analysis. How Rhea-AI works. Not financial advice.